Cingulate Inc (CING) IPO: How to buy the stock? - Kalkine Media

December 08, 2021 06:45 AM PST | By Rupam Roy
Follow us on Google News:

Highlights

  • Cingulate is offering 4,166,666 shares of its common stock and warrants.

  • The offering price is US$6 per share.

  • The gross proceeds from the offering are expected to be around US$25 million.

Biopharmaceutical company Cingulate Inc. is all set to start trading on Nasdaq Capital Market Wednesday. It announced the pricing of its initial public offering (IPO) on Tuesday.

The Kansas City, Missouri-headquartered company specializes in precision time release (PTR) drug delivery technology. It aims to build a portfolio of next-generation pharmaceutical products.

Cingulate is offering 4,166,666 shares of its common stock and accompanying warrants in the IPO.

Also Read: Top growth stocks that gave over 200% return

Each share is sold along with a warrant to purchase one share of common stock for US$6 apiece. Notably, the company is offering all the shares and warrants in the IPO.

Additionally, the firm is providing an over-allotment option of 45 days to underwriters to buy an additional 624,999 shares of its common stock and warrant.

Also Read: Chainlink (LINK) Crypto: How to buy the token?

Cingulate Inc. will start trading on Nasdaq on December 8

Also Read: Globalink IPO: How to buy the stock?

Stock listing & Proceeds

Upon completing the IPO process, the shares and warrants are scheduled to start trading on Nasdaq under the ticker symbol CING and CINGW, respectively. The expected closing date of the offering is Dec 10, 2021, subject to the satisfaction of customary closing conditions. The gross proceeds before underwriting discounts, commissions and projected offering expenses are anticipated to be around US$25 million.

Also Read: Siyata Mobile (SYTA) stock jumps 130% on US$1.3 million order

Cingulate plans to use the proceeds from the IPO in its research and development activities, and pre-commercialization planning of CTx-1301. In addition, the company will invest in the research and development of CTx-1302 and the proof concept study of CTx-2103.

Retail investors can purchase the stocks after they start trading on the exchange. For the year ended on Dec 31, 2020, Cingulate reported a net loss of US$7.18 million. As of Dec 31, 2020, Cingulate’s cash and cash equivalents were US$1.19 million.

Also Read: How far could COVAL token prices climb after Coinbase Pro listing?

Bottomline


Several healthcare companies have debuted in the US stock market this year, demonstrating the industry’s strong confidence in the economy. It has been a year of IPOs despite gloom and doom on the Covid front.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.



Top Listed Companies